Abstract: In one implementation, a microfluidic probe has a non-planar processing surface and an inlet aperture. The shape of the surface may be selected to produce a specific velocity gradient profile across a surface onto which fluid is deposited using the microfluidic probe, for example a constant velocity gradient or a velocity gradient that decreases linearly with distance from the inlet aperture. The microfluidic probe may define and overflow notch in a perimeter edge of the processing surface.

Abstract: Blood typing systems and methods are provided. In one embodiment, the method may be achieved by applying a sample to a surface of a substrate having one or more binding agents immobilized thereon, wherein the one or more binding agents are capable of binding to one or more substances in the sample; substantially removing unbound material from at least a portion of the substrate having immobilized binding agent; and detecting substances bound to the one or more binding agents immobilized on the substrate; wherein the applying the sample to the surface of the substrate step is concurrent with the removing unbound material from at least a portion of the substrate step. Systems and other methods are also described and illustrated.

Abstract: Blood typing systems and methods are provided. In one embodiment, the method may be achieved by applying a sample to a surface of a substrate having one or more binding agents immobilized thereon, wherein the one or more binding agents are capable of binding to one or more substances in the sample; substantially removing unbound material from at least a portion of the substrate having immobilized binding agent; and detecting substances bound to the one or more binding agents immobilized on the substrate; wherein the applying the sample to the surface of the substrate step is concurrent with the removing unbound material from at least a portion of the substrate step. Systems and other methods are also described and illustrated.

Abstract: Blood typing systems and methods are provided. In one embodiment, the method may be achieved by applying a sample to a surface of a substrate having one or more binding agents immobilized thereon, wherein the one or more binding agents are capable of binding to one or more substances in the sample; substantially removing unbound material from at least a portion of the substrate having immobilized binding agent; and detecting substances bound to the one or more binding agents immobilized on the substrate; wherein the applying the sample to the surface of the substrate step is concurrent with the removing unbound material from at least a portion of the substrate step. Systems and other methods are also described and illustrated.

Abstract: The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) comparing the measured level with a cut-off value; (c) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, including the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) including a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: A method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) measuring the level of nucleoside diphosphate kinase A (NDKA) in a biological sample of the individual; (c) comparing the level of proBNP(1-108), or of fragments of proBNP(1-108), and the level of NDKA, with one or several cut-off values; and (d) determining therefrom whether a stroke or a TIA has occurred in the individual.

Abstract: The present invention relates to a method for the in vitro diagnosis of stroke and transient ischemic attack (TIA) in an individual, comprising the following steps: (a) measuring the level of proBNP(1-108), or of fragments of proBNP(1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), in a biological sample of the individual; (b) comparing the measured level with a cut-off value; (c) determining therefrom whether a stroke or a TIA has occurred in the individual.